Looks like there will be another Resverlogix sponsored symposium at this June's ERA-EDTA meeting in Budapest, Hungary entitled "Vascular calcification in kidney disease: Epigenetics as a novel approach?" Last year's symposium at ERA-EDTA 2018 entitled "Epigenetics in CKD & CVD: A potential breakthrough therapy?" was great. Resverlogix has routinely sponsored symposia at the annual ESC meetings as well. Last year's symposium at ESC 2018 "LDL-c: Done Deal, Next Epigenetics?" was excellent. Though this year I expect full BETonMACE data to be presented at ESC 2019, so maybe no ESC symposium this year!

Here is the agenda listed for the upcoming symposium at ERA-EDTA 2019.

Vascular calcification in kidney disease: Epigenetics as a novel approach?

Saturday, June 15, 2019: 13:15 – 14:45 hrs

Educational objectives

• To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with CKD
• To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
• To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
• To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in prevention and management of CKD & CVD

Agenda

• Introduction - Peter Stenvinkel, MD Stockholm, Sweden
• Epigenetic mechanisms targeting ALP: A pathway for prevention? - Marta Ruiz-Ortega, MD,Madrid, Spain
• The role of ALP as predictor of cardiovascular events and vascular calcification in CKD - Mathias Haarhaus, MD, Stockholm, Sweden
• Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition - Vincent M Brandenburg, MD, Aachen, Germany
• Panel discussion - Jurgen Floege, MD Aachen, Germany